Dr. Talat Bessissow, MD PhD
Claim this profileMcGill University Health Center
Studies Crohn's Disease
Studies Inflammatory Bowel Disease
11 reported clinical trials
16 drugs studied
Affiliated Hospitals
Clinical Trials Talat Bessissow, MD PhD is currently running
TAK-279
for Ulcerative Colitis
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study, participants will visit their study clinic several times.
Recruiting0 awards Phase 21 criteria
Extended Mesenteric Excision
for Crohn's Disease
The study is looking at the role of the mesentery in disease recurrence for ileocolic Crohn's disease. It is a prospective study that has been designed to perform extended mesenteric excision on patients undergoing their first ileocolic resection for Crohn's disease. Endoscopic recurrence will be monitored with the hypothesis that patients receiving extended mesenteric ileocolic resection will have reduced endoscopic recurrence at 6 months after resection. (limited mesenteric resection).
Recruiting1 award N/A4 criteria
More about Talat Bessissow, MD PhD
Clinical Trial Related1 year of experience running clinical trials · Led 11 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Talat Bessissow, MD PhD has experience with
- TAK-279
- Vedolizumab
- Itraconazole
- Terbinafine
- Extensive Mesentery Resection
- Chromoendoscopy
Breakdown of trials Talat Bessissow, MD PhD has run
Crohn's Disease
Inflammatory Bowel Disease
Ulcerative Colitis
Ulcer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Talat Bessissow, MD PhD specialize in?
Talat Bessissow, MD PhD focuses on Crohn's Disease and Inflammatory Bowel Disease. In particular, much of their work with Crohn's Disease has involved treating patients, or patients who are undergoing treatment.
Is Talat Bessissow, MD PhD currently recruiting for clinical trials?
Yes, Talat Bessissow, MD PhD is currently recruiting for 7 clinical trials in Montréal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Talat Bessissow, MD PhD has studied deeply?
Yes, Talat Bessissow, MD PhD has studied treatments such as TAK-279, Vedolizumab, Itraconazole.
What is the best way to schedule an appointment with Talat Bessissow, MD PhD?
Apply for one of the trials that Talat Bessissow, MD PhD is conducting.
What is the office address of Talat Bessissow, MD PhD?
The office of Talat Bessissow, MD PhD is located at: McGill University Health Center, Montréal, Quebec H3G1A4 Canada. This is the address for their practice at the McGill University Health Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.